Novo Nordisk is trading at €39.70, down 3.5% today. The decline follows the company's Q2 2026 earnings, where investors reacted to a narrow sales miss for its new Wegovy pill and a trial setback for its next-generation obesity drug, CagriSema. Despite the disappointment, Novo Nordisk raised its full-year 2026 adjusted sales and operating profit outlook, driven by increased expectations for its GLP-1 product sales.